Add BrightSurf on Google Email

UH professor urges better prevention and care of liver disease to reduce burden

Chronic liver disease in the US costs $41.57 billion, with prescription medication expenditures accounting for nearly half of all-cause healthcare expenditures. Poor adherence to antiviral medications is a key factor in preventing disease progression and treatment, with high out-of-pocket costs increasing non-adherence risk.

SourceUniversity of Houston·JournalExpert Review of Pharmacoeconomics & Outcomes Research·DateApr 28, 2026

Use of psychotropics increases already in the early stages of Parkinson’s disease

A recent study from the University of Eastern Finland found that people with Parkinson's disease are using psychotropics more frequently than controls, even before diagnosis. The use of psychotropic medications increases as the disease progresses, reflecting emerging non-motor symptoms and worsening disease progression.

SourceUniversity of Eastern Finland·JournalBritish Journal of Clinical Pharmacology·DateApr 21, 2026

Risk of drug poisoning if gabapentinoid painkillers taken with other medications

A new study by University College London found that gabapentinoids, prescribed for chronic pain, double the risk of hospitalization for drug poisoning when combined with benzodiazepines or opioids. The risk persists even after starting gabapentinoid treatment, suggesting they may not be an effective solution to reduce poisoning risks.

SourceUniversity College London·JournalPLOS Medicine·TypeObservational study·DateApr 16, 2026

Anti-amyloid Alzheimer’s drugs show no clinically meaningful effect

A new Cochrane review of 17 clinical trials found that anti-amyloid Alzheimer's drugs have no significant impact on cognitive decline or dementia severity, but may increase the risk of brain swelling and bleeding. The evidence suggests that these drugs are unlikely to provide clear benefit to patients.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateApr 15, 2026

Penn researchers use AI to surface unreported GLP-1 side effects in Reddit posts

Researchers identified patient-reported symptoms associated with GLP-1s, including menstrual changes, fatigue, and temperature-related complaints, that may not be fully captured in clinical trials or drug labeling. Nearly 4% of Reddit users reported reproductive symptoms, and fatigue was the second most common complaint.

SourceUniversity of Pennsylvania School of Engineering and Applied Science·JournalNature Health·TypeData/statistical analysis·DateApr 10, 2026

New drug combination doubles down on Alzheimer's treatments

Researchers at the University of Waterloo have discovered a safer and more effective way to treat Alzheimer's disease by combining anti-amyloid antibodies with molecules found in grapes, berries, peanuts, and turmeric. This combination approach neutralizes amyloid protein clumping in the brain, leading to better outcomes.

SourceUniversity of Waterloo·JournalACS Chemical Neuroscience·TypeExperimental study·DateApr 9, 2026

Mirtazapine for methamphetamine use disorder

In this randomized clinical trial, mirtazapine effectively reduced methamphetamine use in adults with methamphetamine use disorder. The study's findings have important implications for the treatment of this condition, which currently lacks approved pharmacotherapies.

SourceJAMA Network·JournalJAMA Psychiatry·DateApr 1, 2026

Bleeding events largely outnumber thromboembolic events in patients with cancer during the last phase of life, most patients continue antithrombotic therapy

A study found that cancer patients during the last phase of life experienced more bleeding events than thromboembolic events. Most patients continued their antithrombotic therapy despite increased bleeding risk, with over 28% experiencing at least one bleeding episode.

SourceAmerican Academy of Family Physicians·JournalThe Annals of Family Medicine·DateMar 23, 2026

NRG Oncology/Alliance trial finds immunotherapy did not improve survival when added to chemoradiotherapy for small cell lung cancer

The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.

SourceAlliance for Clinical Trials in Oncology·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateMar 12, 2026

Doubling of new prescriptions for ADHD medications among adults since start of COVID-19 pandemic

New prescriptions for stimulants among adults with ADHD more than doubled since the COVID-19 pandemic, with the largest increases among younger adults. The trend is driven by improved recognition and treatment of ADHD in adulthood, as well as increased access to care and virtual health services.

SourceCanadian Medical Association Journal·JournalCanadian Medical Association Journal·TypeObservational study·DateMar 9, 2026

Low-dose lithium for mild cognitive impairment

Researchers investigated low-dose lithium as a potential treatment for mild cognitive impairment in a pilot clinical trial. The study found that none of the primary outcomes met the significance threshold, but effect size estimates suggest potential benefits for future trials.

SourceJAMA Network·JournalJAMA Neurology·DateMar 2, 2026

GLP-1 drugs combined with healthy lifestyle habits linked with reduced cardiovascular risk among diabetes patients

A new study by Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System found that using GLP-1 receptor agonists in combination with adhering to healthy lifestyle habits significantly reduces cardiovascular risk among individuals with type 2 diabetes. The study showed that these two stra...

SourceHarvard T.H. Chan School of Public Health·JournalThe Lancet Diabetes & Endocrinology·TypeObservational study·DateFeb 25, 2026

UT Health San Antonio research shows Alzheimer’s prevention potential in pairing cannabis ingredient, anti-inflammatory drug

A new study led by Dr. Chu Chen suggests that combining THC with celecoxib may improve cognition and reduce Alzheimer's-related brain pathology in mice. The combination produced better outcomes than low-dose THC alone, including improved learning and memory performance and reduced markers of neuroinflammation.

SourceThe University of Texas at San Antonio Health Science Center·JournalAging and Disease·TypeExperimental study·DateJan 28, 2026

Japanese version of rPATD validated to assess attitudes toward medication reductions among patients and caregivers

The Japanese version of the rPATD questionnaire has been validated to assess attitudes towards medication reductions among older adults and their caregivers in Japan. The tool is reliable, valid, and easily understood, facilitating shared decision-making between healthcare providers and patients.

SourceUniversity of Tsukuba·JournalExploratory Research in Clinical and Social Pharmacy·DateJan 26, 2026

Use of potentially inappropriate medications during end-of-life cancer care: Patterns and factors associated with deprescribing

Researchers analyzed medical records of 1,269 elderly patients with advanced cancer to find that over 70% were prescribed potentially inappropriate medications (PIMs), which declined closer to death. PIM discontinuation was more common among female patients, those with polypharmacy, and palliative care unit admissions.

SourceUniversity of Tsukuba·JournalPalliative Care and Social Practice·DateJan 19, 2026

Alliance trial reveals gene variant may affect prostate cancer drug efficacy

A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...

SourceAlliance for Clinical Trials in Oncology·JournalClinical and Translational Science·TypeExperimental study·DateJan 14, 2026

Lifesaving breakthrough in bacterial behavior

Researchers have made a groundbreaking discovery about how bacteria swim upstream to cause infections, pointing to new designs for biomedical devices that can prevent contamination. The study found that wider channels with faster counterflows are more prone to invasion, but sharp corner designs can inhibit bacterial growth.

SourceUniversity of Pennsylvania·JournalNewton·TypeExperimental study·DateJan 12, 2026